Kurt Losert 
From June 9 – 11, FCF is hosting its sixth Fibrolamellar Scientific Summit. The goal of this meeting is to bring together the fibrolamellar research community to share research knowledge and to collaborate in the search for a cure. To encourage the sharing of unpublished information, the scientific discussions in the main session will be …
Congratulations to Marina Baretti, MD of Johns Hopkins University! On May 30, she was recognized with a Career Development Award (CDA) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This highly prestigious award provides three years of research funding to clinical investigators to establish an independent clinical cancer research program. These awards …
The Fibrolamellar Cancer Foundation is pleased to announce that it has awarded an exploratory research grant to Dr. Hugo Jimenez at Wayne State University to investigate the effectiveness of using low energy electromagnetic fields to treat fibrolamellar carcinoma (FLC). In this study, Dr. Jimenez and his team will conduct initial feasibility testing with a device …
FCF is pleased to announce that it is funding an extension of a clinical trial at the Johns Hopkins Kimmel Cancer Center in Baltimore, MD that tests the ability of a FLC-specific vaccine to produce an immune response against the disease. With this new funding, the trial will be able to enroll 16 additional patients. …
In the video below, Dr. Juliane Walz discusses a new clinical trial that is now open to patient enrollment at The University Hospital Tübingen in Tübingen, Germany. This FusionVAC22_02 clinical trial is designed to test the safety and efficacy of a peptide vaccine to delay or prevent the recurrence of fibrolamellar carcinoma (FLC). The peptide …
Cancers grow through uncontrolled cell proliferation. Repeated rounds of division of single cells to yield “daughter” cells cause tumors to expand exponentially. Cancer therapy aims not only to slow down or prevent cell division, but also to cause the malignant cells to die. Efficient killing is crucial because even a tumor that is barely detectable …
The U.S. Department of Defense has asked FCF to help to recruit community members to serve as consumer reviewers for the Peer Reviewed Cancer Research Program …
In a recent study funded by FCF, scientists at Fred Hutch Cancer Center in Seattle, Washington outlined the potential importance of Polo-like kinase 1 (PLK1) as a promising therapeutic target in FLC. The paper, DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma, was published on April 24 in the journal Gut. The effort was …
FCF is pleased to announce its partnership with Dialectic Therapeutics to supply an experimental drug, DT2216, for a planned clinical trial for fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the manufacturing costs of the drug was crucial to ensure the …